Biodesix Sees FY23 Revenue $50M-$52M Vs $53.29M Est.
Portfolio Pulse from Benzinga Newsdesk
Biodesix has adjusted its 2023 financial outlook due to a change in the timing and assumptions regarding the anticipated collection of revenue from a backlog of previously unrecognized Medicare Advantage claims. The company now expects to generate $50 to $52 million in total revenue in 2023, down from the previous estimate of $53.29 million.
November 08, 2023 | 12:31 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Biodesix's revised 2023 revenue forecast could potentially impact its stock price. The company's revenue is expected to be lower than previously estimated due to changes in Medicare Advantage claims collection.
Biodesix's stock price could potentially be negatively impacted due to the revised 2023 revenue forecast. Investors often react to changes in a company's financial outlook, and a lower than expected revenue forecast could lead to a decrease in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100